Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients.
Among the adverse effects possibly associated with the use of erythropoietin (EPO) in hemodialysis patients is an increased incidence of thrombosis of the vascular access. However, little is known about the effect of EPO on the stenotic lesion in the venous outflow system, which is the leading cause of fistula thrombosis. This study was designed to explore the long-term effects of EPO treatment on progressive fistula stenosis and the plasma concentrations of some potential mediators of neointimal hyperplasia. A cross-sectional and 3-yr prospective, placebo-controlled, pilot study was performed in 30 hemodialysis patients with native arteriovenous fistula. Sixteen patients received EPO and 14 received a placebo. Venous dialysis pressure, urea recirculation, color Doppler sonography, and angiography were used to monitor vascular access patency. Compared with 60 healthy subjects, the hemodialysis patients had elevated plasma levels of platelet-derived growth factor, monocyte chemoattractant protein-1, and interleukin 6, three proteins that might be involved in the neointima formation regulating the proliferation of vascular smooth muscle cells. In addition, these patients had numerous endothelial and hemostatic abnormalities that indicated a thrombophilic state. Eleven patients, six (37.5%) receiving EPO and five (35.7%) taking placebo, developed a progressive stenosis in the venous circuit of the fistula. There was no significant difference in the vascular access, event-free survival over 36 mo between patients receiving EPO therapy and placebo. EPO induced a significant decrease in the plasma values of platelet-derived growth factor and vascular cell adhesion molecule-1 and an increase of monocyte chemoattractant protein-1 concentration. After EPO withdrawal, these parameters returned to pretreatment levels. In conclusion, long-term EPO therapy does not increase the risk of progressive stenosis of native arteriovenous fistula. The use of erythropoietin does not induce any prothrombotic change in hemostatic parameters, and further studies are required to elucidate the theoretically beneficial effects on the plasma concentration of some potential mediators of neointimal formation.
De Marchi
S
S
Department of Internal Medicine, DIPS, University of Udine Medical School, Italy.
Cecchin
E
E
Falleti
E
E
Giacomello
R
R
Stel
G
G
Sepiacci
G
G
Bortolotti
N
N
Zanello
F
F
Gonano
F
F
Bartoli
E
E
D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000097:blood; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects*; D015815:Cell Adhesion Molecules / Q000097:blood; D018932:Chemokine CCL2 / Q000097:blood*; D003251:Constriction, Pathologic; D003430:Cross-Sectional Studies; D016207:Cytokines / Q000097:blood; D004921:Erythropoietin / Q000009:adverse effects*; D005260:Female; D005342:Fibrinolysis; D006487:Hemostasis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000503:physiopathology / Q000628:therapy; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010982:Platelet-Derived Growth Factor / Q000378:metabolism*; D011446:Prospective Studies; D006435:Renal Dialysis / Q000009:adverse effects*; D013924:Thrombophlebitis / Q000209:etiology
D001053:Apolipoproteins; D015815:Cell Adhesion Molecules; D018932:Chemokine CCL2; D016207:Cytokines; D008055:Lipids; D010982:Platelet-Derived Growth Factor; D004921:Erythropoietin